Notice Number: NOT-HL-17-531

Key Dates
Release Date: August 11, 2017

NOT-HL-16-467
NOT-HL-16-468
PAR-16-021

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the NHLBI’s TOPMed program will now emphasize “other omics” and reduce the level of whole genome sequencing for the next two rounds of PAR-16-021, "NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01)". Applicants who are proposing to add other “omics” measurements to address a specific hypothesis will be given preference. For more information, please check our FAQ page periodically, see https://www.nhlbi.nih.gov/research/funding/nhlbi-topmed-omics-phenotypes-heart-lung-and-blood-disorders-x01.

Prior to the submission of an application to PAR-16-021, investigators are strongly encouraged to contact NHLBI staff to ensure that the purpose and scope of their application are aligned with the TOPMed program mission, and meet the technical requirements and analytical capabilities of the program.

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Division of Cardiovascular Sciences
Cashell Jaquish, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0447
Email: jaquishc@nhlbi.nih.gov

Division of Lung Diseases
Weiniu Gan, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0202
Email: ganw2@nhlbi.nih.gov

Division of Blood Diseases and Resources
Pankaj Qasba, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0050
Email: qasbap@nhlbi.nih.gov